Open-label Safety & Efficacy of ZS (Sodium Zirconium Cyclosilicate)10g qd to extend Study ZS-004 in Hyperkalemia.

Study identifier:ZS-004E

ClinicalTrials.gov identifier:NCT02107092

EudraCT identifier:N/A

CTIS identifier:N/A

Study Complete

Official Title

Open-label Extension to Study ZS-004 [Phase 3 Multicenter, Multi-phase, Multi-dose, Prospective, Randomized, Double-blind, Placebo-controlled Maintenance Study of Safety Efficacy of ZS (Sodium Zirconium Cycolsilicate) in Hyperkalemia.]

Medical condition

Hyperkalemia

Phase

Phase 3

Healthy volunteers

No

Study drug

Sodium Zirconium Cyclosilicate

Sex

All

Actual Enrollment

123

Study type

Interventional

Age

18 Years +

Date

Study Start Date: 31 May 2014
Primary Completion Date: 31 Jul 2015
Study Completion Date: 31 Aug 2015

Study design

Allocation: N/A
Endpoint Classification: -
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Supportive Care

Verification:

Verified 01 Jul 2018 by ZS Pharma, Inc.

Sponsors

ZS Pharma, Inc.

Collaborators

-

Inclusion and exclusion criteria